Product Management and Efficacy Evaluation of an Anti- Coagulant Enoxaparin (Clexane) in Pakistan

Abstract

Objective: Enoxaparin (Clexane) is a low molecular weight heparin with a molecular weight of around 4500D. It is a blood thinner used to treat pulmonary embolism, Deep vein thrombosis, unstable angina, non-ST elevated myocardial infarction and STsegment elevation myocardial infarction. This project is designed to evaluate the most widely used Low molecular weight heparin (LMWH), enoxaparin in patients with Acute Coronary Syndrome (ACS) based on prescriptions evaluation. Methods: Prescriptions were collected from different health institutes and were evaluated on the basis of Market Share, MIP data-competitors, MIP data- indication, and on MIP dataspecialty. The study included both male and female patients of age ranging between 50-70 years. The results reflect the prescription patterns of enoxaparin (Clexane) by evaluating 73 prescriptions from major cardiovascular hospitals in Pakistan between February 2008 and October 2008. Results: The prescription pattern showed that physicians in Pakistan have a tendency of prescribing enoxaparin with other drugs. The results also showed that patients were prescribed multiple anti-coagulants concomitantly, including enoxaparin and aspirin. Conclusion: Overall, the analysis of anti-coagulants has indicated that enoxaparin is the drug of choice for the treatment of ACS.